Celebrating a year of immunotherapy/cell and gene therapy in Blood Advances.
作者信息
Bollard Catherine M, Weyrich Andrew S
出版信息
Blood Adv. 2024 Dec 24;8(24):6334-6336. doi: 10.1182/bloodadvances.2024015305.
Abstract
摘要
相似文献
1
Celebrating a year of immunotherapy/cell and gene therapy in Blood Advances.
Blood Adv. 2024 Dec 24;8(24):6334-6336. doi: 10.1182/bloodadvances.2024015305.
2
Celebrating a decade of the .
J Immunother Cancer. 2022 May;10(5). doi: 10.1136/jitc-2022-005207.
3
Celebrating the 15th anniversary of : a reflection on 2022.
Immunotherapy. 2023 Jan;15(1):1-4. doi: 10.2217/imt-2022-0291. Epub 2023 Jan 26.
4
Celebrating a year of clinical and translational research in Blood Advances.
Blood Adv. 2022 Dec 27;6(24):6271-6273. doi: 10.1182/bloodadvances.2022009151.
5
Celebrating a year of cancer research in Blood Advances.
Blood Adv. 2023 Dec 26;7(24):7621-7623. doi: 10.1182/bloodadvances.2023011867.
6
Cancer and radiation therapy: current advances and future directions.
Int J Med Sci. 2012;9(3):193-9. doi: 10.7150/ijms.3635. Epub 2012 Feb 27.
7
The age of immunotherapy-Celebrating STEM CELLS' contribution to understanding mechanisms of immune system development and modulation.
Stem Cells. 2020 Jan;38(1):4-5. doi: 10.1002/stem.3137.
8
: celebrating 10 years of publication.
RSC Adv. 2021 Jul 9;11(39):24054-24056. doi: 10.1039/d1ra90127c. eCollection 2021 Jul 6.
9
Celebrating blood donors amid advances in blood transfusion.
Lancet Haematol. 2023 Jun;10(6):e389. doi: 10.1016/S2352-3026(23)00129-1.
10
Allergic rhinitis and asthma: celebrating 100 years of immunotherapy.
Curr Opin Immunol. 2011 Dec;23(6):808-13. doi: 10.1016/j.coi.2011.07.015. Epub 2011 Aug 19.
本文引用的文献
1
The rules of T-cell engagement: current state of CAR T cells and bispecific antibodies in B-cell lymphomas.
Blood Adv. 2024 Sep 10;8(17):4700-4710. doi: 10.1182/bloodadvances.2021004535.
2
Safety and feasibility of third-party cytotoxic T lymphocytes for high-risk patients with COVID-19.
Blood Adv. 2024 Aug 13;8(15):4113-4124. doi: 10.1182/bloodadvances.2024013344.
3
CAR T-cell toxicities: from bedside to bench, how novel toxicities inform laboratory investigations.
Blood Adv. 2024 Aug 27;8(16):4348-4358. doi: 10.1182/bloodadvances.2024013044.
4
CD70-specific CAR NK cells expressing IL-15 for the treatment of CD19-negative B-cell malignancy.
Blood Adv. 2024 Jun 11;8(11):2635-2645. doi: 10.1182/bloodadvances.2023012202.
5
Reinfusion of CD19 CAR T cells for relapse prevention and treatment in children with acute lymphoblastic leukemia.
Blood Adv. 2024 May 14;8(9):2182-2192. doi: 10.1182/bloodadvances.2024012885.
6
Clinical features of neurotoxicity after CD19 CAR T-cell therapy in mantle cell lymphoma.
Blood Adv. 2024 Mar 26;8(6):1474-1486. doi: 10.1182/bloodadvances.2023011896.
7
Answering the "Doctor, can CAR-T therapy cause cancer?" question in clinic.
Blood Adv. 2024 Feb 27;8(4):895-898. doi: 10.1182/bloodadvances.2023012336.
8
Durable immunity to EBV after rituximab and third-party LMP-specific T cells: a Children's Oncology Group study.
Blood Adv. 2024 Mar 12;8(5):1116-1127. doi: 10.1182/bloodadvances.2023010832.
9
Early predictive factors of failure in autologous CAR T-cell manufacturing and/or efficacy in hematologic malignancies.
Blood Adv. 2024 Jan 23;8(2):337-342. doi: 10.1182/bloodadvances.2023011992.
10
Transient responses and significant toxicities of anti-CD30 CAR T cells for CD30+ lymphomas: results of a phase 1 trial.
Blood Adv. 2024 Feb 13;8(3):802-814. doi: 10.1182/bloodadvances.2023011470.
Zotero 插件